GLP-1 receptor agonists, the medication class behind brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, have rapidly reshaped how clinicians approach type 2 diabetes and obesity. A newer line of research is now asking a different question: could these drugs also reduce the risk of certain cancers? Several large analyses published in 2024 and 2025 suggest the answer may be yes, though experts caution that the evidence is still maturing.
The Obesity-Cancer Connection
Excess body fat is one of the most established modifiable risk factors for cancer. The International Agency for Research on Cancer (IARC) has identified 13 cancers with sufficient evidence linking them to overweight and obesity, including colorectal, postmenopausal breast, endometrial, kidney, liver, pancreatic, and esophageal adenocarcinoma. According to the U.S. Centers for Disease Control and Prevention, these obesity-associated cancers account for roughly 40% of all cancers diagnosed in the United States each year.
Researchers believe several biological pathways drive this association. Adipose tissue, particularly visceral fat, secretes inflammatory cytokines that can promote tumor growth. Obesity also raises circulating insulin and insulin-like growth factor levels, both of which act as mitogens that can encourage cell proliferation. In postmenopausal women, fat tissue becomes a major source of estrogen, which is implicated in hormone-sensitive cancers.
Why Weight Loss Drugs Entered the Picture
GLP-1 receptor agonists were originally developed to improve blood sugar control in type 2 diabetes by enhancing insulin secretion and slowing gastric emptying. Their effect on appetite signaling produces meaningful weight loss, often 15% to 22% of body weight in clinical trials of semaglutide and tirzepatide. Because excess weight drives so much cancer risk, scientists hypothesized that sustained weight loss from these drugs might translate into lower cancer incidence over time.
What the Latest Studies Show
A 2024 cohort study published in JAMA Network Open analyzed electronic health records of more than 1.6 million U.S. adults with type 2 diabetes. Patients who took GLP-1 receptor agonists had a significantly lower risk of 10 of the 13 obesity-associated cancers compared with patients taking insulin, including reductions for esophageal, colorectal, kidney, liver, ovarian, and pancreatic cancers.
A separate analysis from researchers at Case Western Reserve University, also published in JAMA Network Open, compared GLP-1 users with people taking older antidiabetic medications. The study reported a notable reduction in colorectal cancer incidence among GLP-1 users with type 2 diabetes, with the effect appearing even stronger in patients who also had obesity.
Additional research presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting examined breast cancer outcomes. Women with obesity who used GLP-1 drugs showed lower rates of new breast cancer diagnoses over follow-up than matched non-users, though investigators emphasized that randomized trials are still needed to confirm a causal effect.
How Large Is the Effect?
Across studies, reported risk reductions for individual cancers have ranged from roughly 20% to more than 50%, depending on the cancer type, comparison group, and follow-up duration. These are observational findings, meaning they cannot definitively prove that the drugs themselves cause the protection. Other factors, such as differences in healthcare engagement or comorbidities between patients on different therapies, could influence results.
Possible Mechanisms Beyond Weight Loss
Weight loss alone likely explains a large portion of any cancer-protective effect, but emerging research suggests GLP-1 drugs may have additional biological actions. GLP-1 receptors are expressed in the pancreas, intestine, brain, and immune cells, raising the possibility of direct effects on inflammation and cell signaling.
Studies in Cell Metabolism and Nature Reviews Endocrinology have highlighted several candidate mechanisms:
- Reduced systemic inflammation: GLP-1 agonists lower C-reactive protein and several inflammatory cytokines linked to tumor progression.
- Improved insulin sensitivity: Lower circulating insulin reduces a key growth signal for many tumors.
- Loss of visceral fat: Imaging studies show these drugs preferentially reduce metabolically active belly fat.
- Immune modulation: Early laboratory work suggests possible effects on tumor-associated immune cells, though this remains speculative.
Where Evidence Is Strongest and Where It Is Not
The most consistent observational signals so far involve colorectal, endometrial, postmenopausal breast, kidney, and liver cancers. For each of these, weight loss has a well-established protective effect, and GLP-1 use has been linked to lower incidence in multiple large datasets.
Other findings are more mixed. Early concerns about pancreatic cancer risk with GLP-1 drugs have not been confirmed in long-term safety analyses, and some recent studies actually suggest a protective signal. However, the U.S. Food and Drug Administration retains a boxed warning for medullary thyroid carcinoma, a rare cancer that has been linked to GLP-1 drugs in rodent studies. People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 are advised against using these medications.
Important Caveats
Several limitations should temper enthusiasm. The current evidence is largely from observational cohorts, which cannot fully control for confounding. Follow-up periods in many studies are still relatively short, typically two to five years, while many cancers develop over a decade or longer. Randomized controlled trials with cancer as a primary endpoint have not yet been completed.
Experts also note that GLP-1 drugs are not free of side effects. Gastrointestinal symptoms, gallbladder disease, and rare cases of pancreatitis have been reported. Costs remain high, access is uneven, and discontinuation often leads to significant weight regain.
The Bigger Picture
Public health authorities continue to emphasize that lifestyle factors remain central to cancer prevention. The American Institute for Cancer Research estimates that a healthy weight, regular physical activity, a diet rich in plants, limited alcohol intake, and avoiding tobacco could prevent roughly one in three common cancers. GLP-1 drugs may eventually become an important addition to that toolkit for people with obesity, but they are not a substitute for these foundations.
Recommended cancer screenings, including colonoscopy, mammography, and cervical screening, also remain essential regardless of weight loss medication use. Anyone considering or currently taking a GLP-1 drug should discuss personal risk factors, screening schedules, and treatment goals with a qualified healthcare provider.
The Takeaway
Research published over the past two years offers a genuinely encouraging signal: people with obesity who use GLP-1 receptor agonists appear to have lower rates of several obesity-related cancers than those on older therapies. The size of the benefit, the mechanisms involved, and the long-term implications all need confirmation in rigorous randomized trials. For now, the most reliable conclusion is that achieving and maintaining a healthier weight, by whatever evidence-based means a person and their clinician choose, remains one of the most powerful steps available for reducing cancer risk.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.